ASCO shared on X:
“The DREAMM-7 and DREAMM-8 studies established the effectiveness of belamaf-based triplet regimens in patients with R/R MM who had received ≥1 prior line of therapy.
Ben Derman examines the potential of belamaf + Vd and belamaf + Pd for ASCO Daily News.”
Source: ASCO/X